MX2021004868A - Diacuerpos cd123 x cd3 biespecificos para el tratamiento de neoplasias hematologicas. - Google Patents

Diacuerpos cd123 x cd3 biespecificos para el tratamiento de neoplasias hematologicas.

Info

Publication number
MX2021004868A
MX2021004868A MX2021004868A MX2021004868A MX2021004868A MX 2021004868 A MX2021004868 A MX 2021004868A MX 2021004868 A MX2021004868 A MX 2021004868A MX 2021004868 A MX2021004868 A MX 2021004868A MX 2021004868 A MX2021004868 A MX 2021004868A
Authority
MX
Mexico
Prior art keywords
expression
patient
genes
hematologic malignancy
bispecific
Prior art date
Application number
MX2021004868A
Other languages
English (en)
Inventor
Jan Kenneth Davidson
Sara Church
Sergio Rutella
Original Assignee
Macrogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics Inc filed Critical Macrogenics Inc
Publication of MX2021004868A publication Critical patent/MX2021004868A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención está dirigida a un método para tratar una neoplasia maligna hematológica como la leucemia mieloide aguda (AML) o el síndrome mielodisplásico (MDS), que incluye neoplasias hematológicas que son refractivas a agentes quimioterapéuticos y/o hipometilantes. El método se refiere a la administración de una molécula de unión biespecífica CD123 x CD3 a un paciente en una cantidad eficaz para estimular la destrucción de células de dicha neoplasia maligna hematológica en dicho paciente. La presente invención se dirige además a la modalidad de dicho método en donde una muestra celular del paciente evidencia una expresión de uno o más genes objetivo que se incrementa en relación con un nivel de línea de base de expresión de dichos genes, por ejemplo, un nivel de línea de base de expresión de dichos genes en una población de referencia de individuos que padecen neoplasia maligna hematológica, o con respecto al nivel de expresión de un gen de referencia.
MX2021004868A 2018-10-30 2019-10-29 Diacuerpos cd123 x cd3 biespecificos para el tratamiento de neoplasias hematologicas. MX2021004868A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862752659P 2018-10-30 2018-10-30
US201862769078P 2018-11-19 2018-11-19
US201962878368P 2019-07-25 2019-07-25
PCT/US2019/058616 WO2020092404A1 (en) 2018-10-30 2019-10-29 Bispecific cd123 x cd3 diabodies for the treatment of hematologic malignancies

Publications (1)

Publication Number Publication Date
MX2021004868A true MX2021004868A (es) 2021-09-08

Family

ID=70464448

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004868A MX2021004868A (es) 2018-10-30 2019-10-29 Diacuerpos cd123 x cd3 biespecificos para el tratamiento de neoplasias hematologicas.

Country Status (13)

Country Link
US (1) US20210395374A1 (es)
EP (1) EP3873606A4 (es)
JP (1) JP2022513402A (es)
KR (1) KR20210110567A (es)
CN (1) CN113286633A (es)
AU (1) AU2019371243A1 (es)
BR (1) BR112021008283A2 (es)
CA (1) CA3118081A1 (es)
IL (1) IL282827A (es)
MX (1) MX2021004868A (es)
SG (1) SG11202104367RA (es)
WO (1) WO2020092404A1 (es)
ZA (1) ZA202102775B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021257334A1 (en) * 2020-06-18 2021-12-23 Macrogenics, Inc. Use of bispecific cd123 x cd3 diabodies for the treatment of hematologic malignancies
KR20230157315A (ko) 2021-01-28 2023-11-16 리제너론 파마슈티칼스 인코포레이티드 사이토카인 방출 증후군을 치료하기 위한 조성물 및 방법
CA3211006A1 (en) * 2021-02-20 2022-08-25 Kite Pharma, Inc. Gene markers for sellecting immunotherapies
WO2023092119A2 (en) * 2021-11-22 2023-05-25 Ludwig Institute For Cancer Research Ltd Methods for predicting responsiveness to a cancer therapy
TW202346337A (zh) * 2022-03-29 2023-12-01 美商恩格姆生物製藥公司 Ilt3及cd3結合劑以及其使用方法
WO2023201226A1 (en) 2022-04-11 2023-10-19 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR048945A1 (es) * 2004-05-06 2006-06-14 Veridex Llc Pronostico para leucemia mieloide cronica
US8518405B2 (en) * 2009-10-08 2013-08-27 The University Of North Carolina At Charlotte Tumor specific antibodies and uses therefor
EP2839842A1 (en) * 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
US20160272720A1 (en) * 2013-11-06 2016-09-22 Memorial Sloan-Kettering Cancer Center Compositions and Methods for the Treatment of Acute Myeloid Leukemias and Myelodysplastic Syndromes
MX370272B (es) * 2014-03-19 2019-12-09 Cellectis Receptores de antigeno quimerico especifico de cd123 para inmunoterapia de cancer.
EP3364966A1 (en) * 2015-10-23 2018-08-29 Daiichi Sankyo Company, Limited Pharmaceutical composition for use in treating aml and method of treating aml in a subject in need thereof
JP2019517539A (ja) * 2016-06-07 2019-06-24 マクロジェニクス，インコーポレーテッド 併用療法
TWI790206B (zh) * 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
US20210061911A1 (en) * 2017-09-07 2021-03-04 Macrogenics, Inc. Dosing Regiments of Bi-Specific CD123 x CD3 Diabodies in the Treatment of Hematologic Malignancies

Also Published As

Publication number Publication date
EP3873606A4 (en) 2022-10-26
ZA202102775B (en) 2022-03-30
AU2019371243A1 (en) 2021-05-27
US20210395374A1 (en) 2021-12-23
IL282827A (en) 2021-06-30
SG11202104367RA (en) 2021-05-28
WO2020092404A8 (en) 2021-05-20
BR112021008283A2 (pt) 2021-09-14
CA3118081A1 (en) 2020-05-07
KR20210110567A (ko) 2021-09-08
JP2022513402A (ja) 2022-02-07
WO2020092404A1 (en) 2020-05-07
EP3873606A1 (en) 2021-09-08
CN113286633A (zh) 2021-08-20

Similar Documents

Publication Publication Date Title
MX2021004868A (es) Diacuerpos cd123 x cd3 biespecificos para el tratamiento de neoplasias hematologicas.
Jablonska et al. The regulation of pre-metastatic niche formation by neutrophils
PH12020551908A1 (en) Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics
Brenot et al. SNAIL1 action in tumor cells influences macrophage polarization and metastasis in breast cancer through altered GM-CSF secretion
CL2020003071A1 (es) Proteínas de unión multiespecíficas y mejoras con estas
JOP20160154B1 (ar) أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
EA201891428A1 (ru) Комбинация антител к pd-1 и биспецифических антител к cd20/cd3 для лечения злокачественной опухоли
EA201792191A1 (ru) Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли
MX2021008605A (es) Arn terapéutico y anticuerpos anti-pd1 para canceres de tumor sólido en estadio avanzado.
MX2021014193A (es) Moleculas de enlace biespecificas anti-ror1/anti-cd3.
WO2021247794A3 (en) B7h3-targeting proteins and methods of use thereof
BR112023021665A2 (pt) Método para tratar um câncer, e, composição
ATE478076T1 (de) Azaxanthonen zur behandlung von tumoren
Chen et al. Co-dependencies in the tumor immune microenvironment
BR112016023011A2 (pt) tratamento de câncer gástrico
MX2021003262A (es) Metodos de tratamiento.
ZA202213311B (en) Use of bispecific cd123 x cd3 diabodies for the treatment of hematologic malignancies
MX2022014180A (es) Metodos, terapias y usos para tratar cancer.
EA201991870A1 (ru) Лечение рака мочевого пузыря с помощью антитела к pd-l1
MX2021010313A (es) Dosificacion para el tratamiento con anticuerpos anti-tigit y anti-cd20 o anti-cd38.
MX2021015270A (es) Uso de moleculas biespecificas de union a antigeno que se unen a muc16 y cd3 en combinacion con la estimulacion conjunta de 4-1bb.
MX2021015271A (es) Uso de moleculas biespecificas de union a antigeno que se unen a psma y cd3 en combinacion con la estimulacion conjunta de 4-1bb.
MX2021008604A (es) Arn terapeutico para tumores solidos cancerigenos en etapa avanzada.
MX2021003265A (es) Metodos de tratamiento.
MX2020013450A (es) Materiales y métodos para tratar el cancer y los trastornos relacionados con el estrés.